Einführung
Diese Seite bietet eine umfassende Analyse des bekannten Insiderhandels von Ansbert Gadicke. Insider sind leitende Angestellte, Direktoren oder bedeutende Investoren in einem Unternehmen. Es ist für Insider illegal, auf der Grundlage bestimmter, nicht öffentlicher Informationen mit ihren Unternehmen zu handeln. Das bedeutet nicht, dass es für sie illegal ist, irgendwelche Geschäfte in ihren eigenen Unternehmen zu tätigen. Sie müssen jedoch alle Geschäfte der SEC über ein Formular 4 melden. Trotz dieser Einschränkungen deuten akademische Untersuchungen darauf hin, dass Insider im Allgemeinen dazu neigen, den Markt in ihren eigenen Unternehmen zu übertreffen.
Durchschnittliche Handelsrentabilität
Die durchschnittliche Handelsrentabilität ist die durchschnittliche Rendite aller offenen Marktkäufe, die der Insider in den letzten drei Jahren getätigt hat. Um dies zu berechnen, untersuchen wir jeden ungeplanten Kauf, den der Insider auf dem offenen Markt getätigt hat, mit Ausnahme aller Geschäfte, die als Teil eines 10b5-1-Handelsplans gekennzeichnet waren. Anschließend berechnen wir die durchschnittliche Performance dieser Geschäfte über 3, 6 und 12 Monate, wobei wir für jeden dieser Zeiträume den Durchschnitt bilden, um eine endgültige Performance-Kennzahl für jedes Geschäft zu erhalten. Schließlich berechnen wir den Durchschnitt aller Performance-Metriken, um eine Performance-Metrik für den Insider zu ermitteln. Diese Liste enthält nur Insider, die in den letzten zwei Jahren mindestens drei Geschäfte getätigt haben.
Wenn die Handelsrentabilität dieses Insiders "N/A" ist, hat er entweder in den letzten drei Jahren keine Käufe auf dem freien Markt getätigt, oder die von ihm getätigten Geschäfte sind zu kurz her, um eine zuverlässige Performance-Kennzahl zu berechnen.
Aktualisierungshäufigkeit: Täglich
Unternehmen mit gemeldeten Insiderpositionen
Aus den SEC-Filings geht hervor, dass Ansbert Gadicke Beteiligungen an den folgenden Unternehmen gemeldet oder mit ihnen gehandelt hat:
So interpretieren Sie die Diagramme
Die folgenden Diagramme zeigen die Wertentwicklung von Wertpapieren nach jedem offenen, nicht geplanten Handel von Ansbert Gadicke. Nicht geplante Geschäfte sind Geschäfte, die nicht im Rahmen eines 10b5-1-Handelsplans getätigt wurden. Die Aktienperformance wird als kumulative prozentuale Veränderung des Aktienkurses dargestellt. Wenn beispielsweise am 1. Januar 2019 ein Insiderhandel getätigt wurde, zeigt das Diagramm die tägliche prozentuale Veränderung des Wertpapiers bis zum heutigen Tag. Wenn der Aktienkurs in dieser Zeit von $10 auf $15 gestiegen ist, beträgt die kumulative prozentuale Veränderung des Aktienkurses 50 %. Eine Kursveränderung von $10 auf $20 würde 100% betragen und eine Kursveränderung von $10 auf $5 wäre -50%.
Letztendlich versuchen wir festzustellen, wie eng die Geschäfte des Insiders mit den (positiven oder negativen) Überschussrenditen des Aktienkurses korrelieren, um zu sehen, ob der Insider seine Geschäfte zeitlich so abstimmt, dass er von Insiderinformationen profitiert. Stellen Sie sich die Situation vor, dass ein Insider dies tun würde. In dieser Situation würden wir entweder (a) positive Renditen nach Käufen oder (b) negative Renditen nach Verkäufen erwarten. Im Falle von (a) würde das KAUF-Diagramm eine Reihe von aufwärts gerichteten Kurven zeigen, die auf positive Renditen nach jeder Kauftransaktion hinweisen. Im Falle von (b) würde das VERKAUFS-Diagramm eine Reihe von abwärts gerichteten Kurven zeigen, die auf negative Renditen nach jeder Verkaufstransaktion hinweisen.
Dies allein reicht jedoch nicht aus, um Schlussfolgerungen zu ziehen. Wenn sich der Aktienkurs des Unternehmens beispielsweise über viele Jahre hinweg in einem nicht-zyklischen Aufwärtstrend befand, dann würden wir erwarten, dass alle Nach-Kauf-Kurven aufwärts gerichtet sind. Ebenso würden nicht-zyklische Rückgänge über viele Jahre hinweg zu abwärts geneigten Nachhandelsdiagrammen führen. Keines dieser Diagramme würde auf Insiderhandel hindeuten.
Der stärkste Indikator wäre eine Situation, in der der Aktienkurs extrem zyklisch war und es sowohl positive Signale im KAUF-Chart als auch negative im VERKAUF-Chart gab. Diese Situation würde stark auf einen Insider hindeuten, der das Timing von Geschäften zu seinem finanziellen Vorteil nutzt.
Insiderkäufe AVTX / Avalo Therapeutics, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in AVTX / Avalo Therapeutics, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe AVTX / Avalo Therapeutics, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in AVTX / Avalo Therapeutics, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe CGEM / Cullinan Therapeutics, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in AVTX / Avalo Therapeutics, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe CGEM / Cullinan Therapeutics, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in AVTX / Avalo Therapeutics, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-09-01 | CGEM | GADICKE ANSBERT | 790 | 29,4700 | 790 | 29,4700 | 23.281 | 252 | 7.3100 | -17.506 | -75,19 |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe HOWL / Werewolf Therapeutics, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in AVTX / Avalo Therapeutics, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-05-04 | HOWL | GADICKE ANSBERT | 245.000 | 16,0000 | 245.000 | 16,0000 | 3.920.000 | 59 | 20.3100 | 1.055.950 | 26,94 |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe HOWL / Werewolf Therapeutics, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in AVTX / Avalo Therapeutics, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-27 | HOWL | GADICKE ANSBERT | 4.386 | 1,0500 | 4.386 | 1,0500 | 4.605 | 295 | 0.5493 | -2.196 | -47,68 |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe PCRX / Pacira BioSciences, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in AVTX / Avalo Therapeutics, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe PCRX / Pacira BioSciences, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in AVTX / Avalo Therapeutics, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe RYTM / Rhythm Pharmaceuticals, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in AVTX / Avalo Therapeutics, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-10-10 | RYTM | MPM BIOVENTURES V, L.P. | 100.000 | 17,0000 | 100.000 | 17,0000 | 1.700.000 | 268 | 35.85 | 1.885.000 | 110,88 |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe RYTM / Rhythm Pharmaceuticals, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in AVTX / Avalo Therapeutics, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe SNDX / Syndax Pharmaceuticals, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in AVTX / Avalo Therapeutics, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe SNDX / Syndax Pharmaceuticals, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in AVTX / Avalo Therapeutics, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe TRDA / Entrada Therapeutics, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in AVTX / Avalo Therapeutics, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Max |
Preis bei Max |
Max Gewinn ($) |
Max Rendite (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-11-02 | TRDA | MPM BioVentures 2014, L.P. | 100.000 | 20,0000 | 100.000 | 20,0000 | 2.000.000 | 15 | 35 | 1.500.000 | 75,00 |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe TRDA / Entrada Therapeutics, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in AVTX / Avalo Therapeutics, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderkäufe VSTM / Verastem, Inc. - Kurzfristige Gewinnanalyse
In diesem Abschnitt analysieren wir die Rentabilität jedes ungeplanten Insiderkaufs, der auf dem freien Markt in AVTX / Avalo Therapeutics, Inc. getätigt wurde. Diese Analyse hilft zu verstehen, ob der Insider beständig abnormale Renditen erzielt und es sich lohnt, ihm zu folgen. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel, und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Käufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Insiderverkäufe VSTM / Verastem, Inc. - Kurzfristige Verlustanalyse
In diesem Abschnitt analysieren wir die kurzfristige Verlustvermeidung jedes ungeplanten Insider-Verkaufs auf dem freien Markt in AVTX / Avalo Therapeutics, Inc.. Ein konsistentes Muster der Verlustvermeidung kann darauf hindeuten, dass zukünftige Verkaufstransaktionen Kursrückgänge vorhersagen können. Diese Analyse bezieht sich auf ein Jahr nach jedem Handel und die Ergebnisse sind theoretisch.
Die folgende Tabelle zeigt die jüngsten Verkäufe am offenen Markt, die nicht Teil eines automatischen Handelsplans waren.
| Handelsdatum | Ticker | Insider | Berichtete Aktien |
Berichteter Preis |
Angepasste Aktien |
Angepasster Preis |
Kostenbasis | Tage bis Min |
Preis bei Min |
Max Verlust Vermieden ($) |
Max. Verlust Vermieden (%) |
|---|---|---|---|---|---|---|---|
| Für diese Insider- und Wertpapierkombination sind keine ungeplanten Open-Market-Trades bekannt |
Angepasster Preis ist der an den Split angepasste Preis. Angepasste Aktien ist die an den Split angepasste Anzahl der Aktien.
Geschichte des Insiderhandels
Diese Tabelle zeigt die vollständige Liste der von Ansbert Gadicke getätigten Insidergeschäfte, die der Securities Exchange Commission (SEC) gemeldet wurden.
| Datum der Einreichung | Tran Datum | Form | Ticker | Wertpapier | Code | Aktien | Verbleibende Aktien | Prozent Änderung |
Aktie Preis |
Tran Wert |
Verbleibender Wert |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-14 |
|
4 | AKTS |
Aktis Oncology, Inc.
Common Stock |
P - Purchase | 1.112.777 | 10.260.064 | 12,17 | 18,00 | 20.029.986 | 184.681.152 | |
| 2026-01-14 |
|
4 | AKTS |
Aktis Oncology, Inc.
Common Stock |
C - Conversion | 1.577.119 | 9.147.287 | 20,83 | ||||
| 2026-01-14 |
|
4 | AKTS |
Aktis Oncology, Inc.
Common Stock |
C - Conversion | 5.914.197 | 7.570.168 | 357,14 | ||||
| 2026-01-14 |
|
4 | AKTS |
Aktis Oncology, Inc.
Common Stock |
C - Conversion | 1.314.262 | 1.655.971 | 384,61 | ||||
| 2026-01-08 | 3 | AKTS |
Aktis Oncology, Inc.
Common Stock |
341.709 | ||||||||
| 2025-12-04 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -83.230 | 4.784.111 | -1,71 | 0,97 | -80.733 | 4.640.588 |
| 2025-12-04 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -57.225 | 4.867.341 | -1,16 | 0,87 | -49.786 | 4.234.587 |
| 2025-12-04 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -59.277 | 4.924.566 | -1,19 | 0,89 | -52.757 | 4.382.864 |
| 2025-12-01 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -60.917 | 4.983.843 | -1,21 | 0,94 | -57.262 | 4.684.812 |
| 2025-12-01 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -20.277 | 5.044.760 | -0,40 | 0,99 | -20.074 | 4.994.312 |
| 2025-12-01 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -60.733 | 5.065.037 | -1,18 | 0,98 | -59.518 | 4.963.736 |
| 2025-11-25 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -42.533 | 5.125.770 | -0,82 | 0,92 | -39.130 | 4.715.708 |
| 2025-11-25 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -88.802 | 5.168.303 | -1,69 | 0,98 | -87.026 | 5.064.937 |
| 2025-11-25 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -64.331 | 5.257.105 | -1,21 | 0,83 | -53.395 | 4.363.397 |
| 2025-11-20 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -41.152 | 5.321.436 | -0,77 | 0,89 | -36.625 | 4.736.078 |
| 2025-11-20 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -66.324 | 5.362.588 | -1,22 | 0,94 | -62.345 | 5.040.833 |
| 2025-11-20 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -52.627 | 5.428.912 | -0,96 | 0,93 | -48.943 | 5.048.888 |
| 2025-11-17 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -57.061 | 5.481.539 | -1,03 | 0,95 | -54.208 | 5.207.462 |
| 2025-11-17 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -61.640 | 5.538.600 | -1,10 | 0,93 | -57.325 | 5.150.898 |
| 2025-11-17 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -90.951 | 5.600.240 | -1,60 | 0,98 | -89.132 | 5.488.235 |
| 2025-11-12 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -40.669 | 5.691.191 | -0,71 | 1,09 | -44.329 | 6.203.398 |
| 2025-11-12 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -55.810 | 5.731.860 | -0,96 | 1,14 | -63.623 | 6.534.320 |
| 2025-11-12 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -48.570 | 5.787.670 | -0,83 | 1,18 | -57.313 | 6.829.451 |
| 2025-11-12 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -68.480 | 5.836.240 | -1,16 | 1,11 | -76.013 | 6.478.226 |
| 2025-11-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -54.452 | 5.904.720 | -0,91 | 1,21 | -65.887 | 7.144.711 |
| 2025-11-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -47.950 | 5.959.172 | -0,80 | 1,22 | -58.499 | 7.270.190 |
| 2025-11-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -140.488 | 6.007.122 | -2,29 | 1,22 | -171.395 | 7.328.689 |
| 2025-11-03 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -94.063 | 6.147.610 | -1,51 | 1,29 | -121.341 | 7.930.417 |
| 2025-11-03 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -114.044 | 6.241.673 | -1,79 | 1,28 | -145.976 | 7.989.341 |
| 2025-11-03 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -86.936 | 6.355.717 | -1,35 | 1,43 | -124.318 | 9.088.675 |
| 2025-10-29 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -134.240 | 6.442.653 | -2,04 | 1,55 | -208.072 | 9.986.112 |
| 2025-10-29 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -69.068 | 6.576.893 | -1,04 | 1,64 | -113.272 | 10.786.105 |
| 2025-10-29 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | X | -72.709 | 6.645.961 | -1,08 | 1,72 | -125.059 | 11.431.053 |
| 2025-05-15 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | -1.031.931 | 3.452.797 | -23,01 | 8,06 | -8.317.364 | 27.829.544 | |
| 2025-04-30 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
S - Sale | -4.386 | 6.718.670 | -0,07 | 1,05 | -4.605 | 7.054.604 | |
| 2025-04-30 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
X - Other | 50.873 | 6.723.056 | 0,76 | 0,09 | 4.579 | 605.075 | |
| 2024-12-12 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Common Stock |
S - Sale | -21.787 | 4.381.062 | -0,49 | 20,23 | -440.751 | 88.628.884 | |
| 2024-12-12 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Common Stock |
S - Sale | -22.935 | 4.402.849 | -0,52 | 20,77 | -476.360 | 91.447.174 | |
| 2023-06-05 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
J - Other | -3.370.982 | 0 | -100,00 | ||||
| 2023-06-05 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
J - Other | -3.854.963 | 0 | -100,00 | ||||
| 2023-06-05 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
J - Other | -304.001 | 0 | -100,00 | ||||
| 2023-05-24 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
S - Sale | -70.170 | 304.001 | -18,75 | 1,88 | -131.920 | 571.522 | |
| 2023-05-24 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
X - Other | 178.269 | 374.171 | 91,00 | 0,74 | 131.919 | 276.887 | |
| 2023-02-10 |
|
5 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
M - Exercise | 350.938 | 595.489 | 143,50 | 4,30 | 1.509.033 | 2.560.603 | |
| 2022-08-01 |
|
4 | ALVR |
Allovir, Inc.
Common Stock |
A - Award | 3.253.796 | 16.674.766 | 24,24 | 4,61 | 15.000.000 | 76.870.671 | |
| 2022-05-19 |
|
4 | ALVR |
Allovir, Inc.
Stock Option (Right to Buy) |
A - Award | 27.500 | 27.500 | |||||
| 2022-03-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Stock Option (Right to Buy) |
A - Award | 7.800 | 7.800 | |||||
| 2022-01-06 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | -30.347 | 4.484.728 | -0,67 | 42,03 | -1.275.484 | 188.493.118 | |
| 2022-01-06 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | -12.829 | 4.515.075 | -0,28 | 46,47 | -596.164 | 209.815.535 | |
| 2022-01-06 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | -11.318 | 4.527.904 | -0,25 | 45,32 | -512.932 | 205.204.609 | |
| 2022-01-06 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | -32.396 | 4.539.222 | -0,71 | 43,20 | -1.399.507 | 196.094.390 | |
| 2022-01-06 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | -158.579 | 4.571.618 | -3,35 | 42,05 | -6.668.247 | 192.236.537 | |
| 2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -2.499 | 4.730.197 | -0,05 | 34,11 | -85.241 | 161.347.020 |
| 2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -30.059 | 4.732.696 | -0,63 | 33,15 | -996.456 | 156.888.872 |
| 2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -100 | 4.762.755 | 0,00 | 35,04 | -3.504 | 166.886.935 |
| 2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -850 | 4.762.855 | -0,02 | 34,08 | -28.968 | 162.318.098 |
| 2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.960 | 4.763.705 | -0,04 | 33,57 | -65.797 | 159.917.577 |
| 2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -14.173 | 4.765.665 | -0,30 | 32,35 | -458.497 | 154.169.263 |
| 2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -300 | 4.779.838 | -0,01 | 36,26 | -10.878 | 173.316.926 |
| 2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -4.047 | 4.780.138 | -0,08 | 35,44 | -143.426 | 169.408.091 |
| 2021-12-07 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -29.402 | 4.784.185 | -0,61 | 34,68 | -1.019.661 | 165.915.536 |
| 2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -12.434 | 4.813.587 | -0,26 | 34,83 | -433.076 | 167.657.235 |
| 2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -49.796 | 4.826.021 | -1,02 | 33,74 | -1.680.117 | 162.829.949 |
| 2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.500 | 4.875.817 | -0,03 | 35,34 | -53.010 | 172.311.373 |
| 2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -9.131 | 4.877.317 | -0,19 | 34,61 | -316.024 | 168.803.941 |
| 2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.111 | 4.886.448 | -0,21 | 33,82 | -341.954 | 165.259.671 |
| 2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -46.992 | 4.896.559 | -0,95 | 35,19 | -1.653.648 | 172.309.911 |
| 2021-12-02 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -9.809 | 4.943.551 | -0,20 | 34,62 | -339.588 | 171.145.736 |
| 2021-11-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -500 | 4.953.360 | -0,01 | 35,37 | -17.685 | 175.200.343 |
| 2021-11-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -16.856 | 4.953.860 | -0,34 | 34,46 | -580.858 | 170.710.016 |
| 2021-11-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.258 | 4.970.716 | -0,21 | 36,03 | -369.596 | 179.094.897 |
| 2021-11-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.952 | 4.980.974 | -0,22 | 35,49 | -388.686 | 176.774.767 |
| 2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -21.965 | 4.991.926 | -0,44 | 37,02 | -813.144 | 184.801.101 |
| 2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -30.696 | 5.013.891 | -0,61 | 36,05 | -1.106.591 | 180.750.771 |
| 2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -8.147 | 5.044.587 | -0,16 | 35,20 | -286.774 | 177.569.462 |
| 2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -600 | 5.052.734 | -0,01 | 36,50 | -21.900 | 184.424.791 |
| 2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -32.876 | 5.053.334 | -0,65 | 36,21 | -1.190.440 | 182.981.224 |
| 2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -19.758 | 5.086.210 | -0,39 | 37,81 | -747.050 | 192.309.600 |
| 2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -15.575 | 5.105.986 | -0,30 | 37,16 | -578.767 | 189.738.440 |
| 2021-11-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
J - Other | -15.671 | 5.121.543 | -0,31 | ||||
| 2021-11-04 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -3.683.241 | 0 | -100,00 | ||||
| 2021-11-04 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -27.617.675 | 0 | -100,00 | ||||
| 2021-11-04 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Common Stock |
P - Purchase | 100.000 | 4.425.784 | 2,31 | 20,00 | 2.000.000 | 88.515.680 | |
| 2021-11-04 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Common Stock |
C - Conversion | 509.024 | 4.325.784 | 13,34 | ||||
| 2021-11-04 |
|
4 | TRDA |
Entrada Therapeutics, Inc.
Common Stock |
C - Conversion | 3.816.760 | 3.816.760 | |||||
| 2021-10-18 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.320 | 5.137.214 | -0,20 | 27,14 | -280.085 | 139.423.988 |
| 2021-10-18 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.413 | 5.147.534 | -0,07 | 28,01 | -95.598 | 144.182.427 |
| 2021-10-18 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -14.882 | 5.150.947 | -0,29 | 27,53 | -409.701 | 141.805.571 |
| 2021-10-14 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -45.719 | 5.165.829 | -0,88 | 27,30 | -1.248.129 | 141.027.132 |
| 2021-10-14 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -35.023 | 5.211.548 | -0,67 | 27,13 | -950.174 | 141.389.297 |
| 2021-10-14 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -14.260 | 5.246.571 | -0,27 | 27,09 | -386.303 | 142.129.608 |
| 2021-10-12 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -81.684 | 5.260.831 | -1,53 | 27,24 | -2.225.072 | 143.305.036 |
| 2021-10-12 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.400 | 5.342.515 | -0,06 | 27,01 | -91.834 | 144.301.330 |
| 2021-10-12 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.922 | 5.345.915 | -0,04 | 27,00 | -51.894 | 144.339.705 |
| 2021-10-05 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -34.659 | 5.347.837 | -0,64 | 27,06 | -937.873 | 144.712.469 |
| 2021-10-05 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -11.471 | 5.382.496 | -0,21 | 27,00 | -309.717 | 145.327.392 |
| 2021-09-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.836 | 5.393.967 | -0,07 | 27,00 | -103.572 | 145.637.109 |
| 2021-09-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -32.154 | 5.397.803 | -0,59 | 27,00 | -868.158 | 145.740.681 |
| 2021-09-27 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -19.455 | 5.429.957 | -0,36 | 27,09 | -527.036 | 147.097.535 |
| 2021-09-27 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -8.221 | 5.449.412 | -0,15 | 27,81 | -228.626 | 151.548.148 |
| 2021-09-27 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.200 | 5.457.633 | -0,02 | 28,38 | -34.056 | 154.887.625 |
| 2021-09-27 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -60.600 | 5.458.833 | -1,10 | 27,96 | -1.694.376 | 152.628.971 |
| 2021-09-23 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -23.921 | 5.519.433 | -0,43 | 27,54 | -658.784 | 152.005.185 |
| 2021-09-23 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -32.858 | 5.543.354 | -0,59 | 27,47 | -902.609 | 152.275.934 |
| 2021-09-20 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -3.124 | 7.648.268 | -0,04 | 29,06 | -90.783 | 222.258.668 |
| 2021-09-20 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -432 | 244.551 | -0,18 | 29,06 | -12.554 | 7.106.652 |
| 2021-09-20 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -22.930 | 5.576.212 | -0,41 | 27,84 | -638.371 | 155.241.742 |
| 2021-09-20 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -17.743 | 5.599.142 | -0,32 | 27,03 | -479.593 | 151.344.808 |
| 2021-09-20 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -76.473 | 5.616.885 | -1,34 | 28,82 | -2.203.952 | 161.878.626 |
| 2021-09-20 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -35.565 | 5.693.358 | -0,62 | 28,47 | -1.012.536 | 162.089.902 |
| 2021-09-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -6.425 | 7.651.392 | -0,08 | 29,16 | -187.353 | 223.114.591 |
| 2021-09-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -888 | 244.983 | -0,36 | 29,16 | -25.894 | 7.143.704 |
| 2021-09-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -7.106 | 7.657.817 | -0,09 | 29,17 | -207.282 | 223.378.522 |
| 2021-09-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -982 | 245.871 | -0,40 | 29,17 | -28.645 | 7.172.057 |
| 2021-09-16 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.659 | 5.728.923 | -0,03 | 28,15 | -46.701 | 161.269.182 |
| 2021-09-16 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -38.677 | 5.730.582 | -0,67 | 27,79 | -1.074.834 | 159.252.874 |
| 2021-09-16 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.063 | 5.769.259 | -0,10 | 27,99 | -169.703 | 161.481.559 |
| 2021-09-16 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -30.018 | 5.775.322 | -0,52 | 27,50 | -825.495 | 158.821.355 |
| 2021-09-13 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -3.595 | 7.664.923 | -0,05 | 29,10 | -104.614 | 223.049.259 |
| 2021-09-13 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -497 | 246.853 | -0,20 | 29,10 | -14.463 | 7.183.422 |
| 2021-09-13 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -5.931 | 7.668.518 | -0,08 | 29,04 | -172.236 | 222.693.763 |
| 2021-09-13 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -820 | 247.350 | -0,33 | 29,04 | -23.813 | 7.183.044 |
| 2021-09-13 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -13.727 | 7.674.449 | -0,18 | 29,35 | -402.887 | 225.245.078 |
| 2021-09-13 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.898 | 248.170 | -0,76 | 29,35 | -55.706 | 7.283.790 |
| 2021-09-13 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -35.785 | 5.805.340 | -0,61 | 27,64 | -989.097 | 160.459.598 |
| 2021-09-13 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -11.330 | 5.841.125 | -0,19 | 28,73 | -325.511 | 167.815.521 |
| 2021-09-13 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -11.313 | 5.852.455 | -0,19 | 27,86 | -315.180 | 163.049.396 |
| 2021-09-13 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -38.028 | 5.863.768 | -0,64 | 28,97 | -1.101.671 | 169.873.359 |
| 2021-09-08 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -10.842 | 7.688.176 | -0,14 | 29,11 | -315.611 | 223.802.803 |
| 2021-09-08 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.499 | 250.068 | -0,60 | 29,11 | -43.636 | 7.279.479 |
| 2021-09-08 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -25.067 | 7.699.018 | -0,32 | 29,04 | -727.946 | 223.579.483 |
| 2021-09-08 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -3.465 | 251.567 | -1,36 | 29,04 | -100.624 | 7.305.506 |
| 2021-09-08 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -12.731 | 7.724.085 | -0,16 | 29,60 | -376.838 | 228.632.916 |
| 2021-09-08 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.760 | 255.032 | -0,69 | 29,60 | -52.096 | 7.548.947 |
| 2021-09-08 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.573 | 5.901.796 | -0,03 | 29,10 | -45.774 | 171.742.264 |
| 2021-09-08 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -18.663 | 5.903.369 | -0,32 | 28,61 | -533.948 | 168.895.387 |
| 2021-09-08 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
J - Other | -31.340 | 5.922.032 | -0,53 | ||||
| 2021-09-08 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -50.996 | 5.953.372 | -0,85 | 29,18 | -1.488.063 | 173.719.395 |
| 2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -15.757 | 7.736.816 | -0,20 | 29,46 | -464.201 | 227.926.599 |
| 2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -2.178 | 256.792 | -0,84 | 29,46 | -64.164 | 7.565.092 |
| 2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -5.714 | 7.752.573 | -0,07 | 29,47 | -168.392 | 228.468.326 |
| 2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | -790 | 258.970 | -0,30 | 29,47 | -23.281 | 7.631.846 | |
| 2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.553 | 7.758.287 | -0,02 | 30,14 | -46.807 | 233.834.770 |
| 2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -215 | 259.760 | -0,08 | 30,14 | -6.480 | 7.829.166 |
| 2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.285 | 7.759.840 | -0,02 | 29,43 | -37.818 | 228.372.091 |
| 2021-09-02 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -177 | 259.975 | -0,07 | 29,43 | -5.209 | 7.651.064 |
| 2021-08-31 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -31.001 | 7.761.125 | -0,40 | 29,30 | -908.329 | 227.400.962 |
| 2021-08-31 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -4.285 | 260.152 | -1,62 | 29,30 | -125.550 | 7.622.454 |
| 2021-08-31 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -13.357 | 7.792.126 | -0,17 | 29,09 | -388.555 | 226.672.945 |
| 2021-08-31 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.846 | 264.437 | -0,69 | 29,09 | -53.700 | 7.692.472 |
| 2021-08-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -1.713 | 7.805.483 | -0,02 | 29,09 | -49.831 | 227.061.500 |
| 2021-08-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -237 | 266.283 | -0,09 | 29,09 | -6.894 | 7.746.172 |
| 2021-08-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -50.882 | 7.807.196 | -0,65 | 29,48 | -1.500.001 | 230.156.138 |
| 2021-08-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -7.025 | 266.520 | -2,57 | 29,48 | -207.097 | 7.857.010 |
| 2021-08-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -53.359 | 7.858.018 | -0,67 | 29,11 | -1.553.280 | 228.746.904 |
| 2021-08-25 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -7.376 | 273.545 | -2,63 | 29,11 | -214.715 | 7.962.895 |
| 2021-08-12 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -2.510 | 7.911.377 | -0,03 | 29,05 | -72.916 | 229.825.502 |
| 2021-08-12 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
S - Sale | X | -347 | 280.921 | -0,12 | 29,05 | -10.080 | 8.160.755 |
| 2021-07-13 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -711 | 3.882.485 | -0,02 | 34,10 | -24.245 | 132.392.738 |
| 2021-07-13 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -57.301 | 3.883.196 | -1,45 | 33,58 | -1.924.168 | 130.397.722 |
| 2021-07-13 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -4.067 | 3.940.497 | -0,10 | 33,06 | -134.455 | 130.272.831 |
| 2021-06-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -2.700 | 3.944.564 | -0,07 | 33,29 | -89.883 | 131.314.536 |
| 2021-06-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -2.700 | 3.947.264 | -0,07 | 34,82 | -94.014 | 137.443.732 |
| 2021-06-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -13.800 | 3.949.964 | -0,35 | 34,06 | -470.028 | 134.535.774 |
| 2021-06-28 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -22.567 | 3.963.764 | -0,57 | 33,51 | -756.220 | 132.825.732 |
| 2021-06-28 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -6.121 | 3.986.331 | -0,15 | 33,53 | -205.237 | 133.661.678 |
| 2021-06-23 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -1.410 | 3.992.452 | -0,04 | 32,98 | -46.502 | 131.671.067 |
| 2021-06-23 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -429 | 3.993.862 | -0,01 | 34,09 | -14.625 | 136.150.756 |
| 2021-06-23 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -3.371 | 3.994.291 | -0,08 | 33,36 | -112.457 | 133.249.548 |
| 2021-06-23 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -31.788 | 3.997.662 | -0,79 | 34,63 | -1.100.818 | 138.439.035 |
| 2021-06-23 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -5.800 | 4.029.450 | -0,14 | 33,80 | -196.040 | 136.195.410 |
| 2021-06-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -3.199 | 4.035.250 | -0,08 | 34,03 | -108.862 | 137.319.558 |
| 2021-06-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -5.801 | 4.038.449 | -0,14 | 33,46 | -194.101 | 135.126.504 |
| 2021-06-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -1.708 | 4.044.250 | -0,04 | 34,12 | -58.277 | 137.989.810 |
| 2021-06-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -30.810 | 4.045.958 | -0,76 | 33,78 | -1.040.762 | 136.672.461 |
| 2021-06-16 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -4.227 | 4.076.768 | -0,10 | 33,33 | -140.886 | 135.878.677 |
| 2021-06-16 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -2.000 | 4.080.995 | -0,05 | 33,09 | -66.180 | 135.040.125 |
| 2021-06-10 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -24.368 | 4.082.995 | -0,59 | 34,79 | -847.763 | 142.047.396 |
| 2021-06-10 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -10.862 | 4.107.363 | -0,26 | 34,42 | -373.870 | 141.375.434 |
| 2021-06-10 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -17.155 | 4.118.225 | -0,41 | 33,41 | -573.149 | 137.589.897 |
| 2021-06-10 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -9.045 | 4.135.380 | -0,22 | 32,80 | -296.676 | 135.640.464 |
| 2021-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -19.017 | 4.144.425 | -0,46 | 32,96 | -626.800 | 136.600.248 |
| 2021-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -1.700 | 4.163.442 | -0,04 | 32,25 | -54.825 | 134.271.004 |
| 2021-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -2.400 | 4.165.142 | -0,06 | 30,74 | -73.776 | 128.036.465 |
| 2021-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -4.694 | 4.167.542 | -0,11 | 31,28 | -146.828 | 130.360.714 |
| 2021-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -8.042 | 4.172.236 | -0,19 | 30,80 | -247.694 | 128.504.869 |
| 2021-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -22.296 | 4.180.278 | -0,53 | 31,92 | -711.688 | 133.434.474 |
| 2021-06-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -297 | 4.202.574 | -0,01 | 32,42 | -9.629 | 136.247.449 |
| 2021-06-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -5.918 | 4.202.871 | -0,14 | 31,83 | -188.370 | 133.777.384 |
| 2021-06-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -15.141 | 4.208.789 | -0,36 | 32,50 | -492.082 | 136.785.642 |
| 2021-06-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -16.742 | 4.223.930 | -0,39 | 32,67 | -546.961 | 137.995.793 |
| 2021-06-02 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -25.118 | 6.328.095 | -0,40 | 20,50 | -514.919 | 129.725.948 |
| 2021-06-02 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -18.491 | 6.353.213 | -0,29 | 20,44 | -377.956 | 129.859.674 |
| 2021-06-02 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -100 | 6.371.704 | 0,00 | 22,60 | -2.260 | 144.000.510 |
| 2021-06-02 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.100 | 6.371.804 | -0,05 | 21,92 | -67.952 | 139.669.944 |
| 2021-06-02 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.685 | 6.374.904 | -0,17 | 20,88 | -223.103 | 133.107.996 |
| 2021-05-27 |
|
4 | ALVR |
Allovir, Inc.
Stock Option (Right to Buy) |
A - Award | 22.500 | 22.500 | |||||
| 2021-05-27 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -13.961 | 6.385.589 | -0,22 | 20,26 | -282.850 | 129.372.033 |
| 2021-05-27 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.198 | 6.399.550 | -0,05 | 20,04 | -64.088 | 128.246.982 |
| 2021-05-27 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -3.624 | 4.240.672 | -0,09 | 33,16 | -120.172 | 140.620.684 |
| 2021-05-27 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -4.327 | 4.244.296 | -0,10 | 32,81 | -141.969 | 139.255.352 |
| 2021-05-27 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -1.704 | 4.248.623 | -0,04 | 33,01 | -56.249 | 140.247.045 |
| 2021-05-27 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -22.332 | 4.250.327 | -0,52 | 32,74 | -731.150 | 139.155.706 |
| 2021-05-27 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -100 | 4.272.659 | 0,00 | 33,59 | -3.359 | 143.518.616 |
| 2021-05-27 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -6.472 | 4.272.759 | -0,15 | 32,87 | -212.735 | 140.445.588 |
| 2021-05-24 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -5.000 | 6.402.748 | -0,08 | 20,12 | -100.600 | 128.823.290 |
| 2021-05-24 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.907 | 6.407.748 | -0,17 | 20,21 | -220.430 | 129.500.587 |
| 2021-05-24 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -18.653 | 4.279.231 | -0,43 | 34,28 | -639.425 | 146.692.039 |
| 2021-05-24 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -3.547 | 4.297.884 | -0,08 | 33,30 | -118.115 | 143.119.537 |
| 2021-05-24 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -302.669 | 4.301.431 | -6,57 | 34,80 | -10.532.881 | 149.689.799 |
| 2021-05-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -11.713 | 6.418.655 | -0,18 | 20,34 | -238.242 | 130.555.443 |
| 2021-05-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -17.833 | 6.430.368 | -0,28 | 20,39 | -363.615 | 131.115.204 |
| 2021-05-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -18.402 | 6.448.201 | -0,28 | 20,67 | -380.369 | 133.284.315 |
| 2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -600 | 4.604.100 | -0,01 | 35,19 | -21.114 | 162.018.279 |
| 2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -9.357 | 4.604.700 | -0,20 | 34,66 | -324.314 | 159.598.902 |
| 2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -4.400 | 4.614.057 | -0,10 | 35,00 | -154.000 | 161.491.995 |
| 2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -9.143 | 4.618.457 | -0,20 | 34,23 | -312.965 | 158.089.783 |
| 2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -21.834 | 4.627.600 | -0,47 | |||
| 2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -90 | 4.649.434 | 0,00 | 35,14 | -3.163 | 163.381.111 |
| 2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -8.541 | 4.649.524 | -0,18 | 34,61 | -295.604 | 160.920.026 |
| 2021-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | X | -14.773 | 4.658.065 | -0,32 | 33,90 | -500.805 | 157.908.404 |
| 2021-05-17 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -4.666 | 6.466.603 | -0,07 | 20,07 | -93.647 | 129.784.722 |
| 2021-05-17 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.900 | 6.471.269 | -0,11 | 20,04 | -138.276 | 129.684.231 |
| 2021-05-17 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -4.855 | 6.478.169 | -0,07 | 20,06 | -97.391 | 129.952.070 |
| 2021-05-12 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -29.684 | 6.483.024 | -0,46 | 20,53 | -609.413 | 133.096.483 |
| 2021-05-12 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -7.672 | 6.512.708 | -0,12 | 21,51 | -165.025 | 140.088.349 |
| 2021-05-12 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -13.773 | 6.520.380 | -0,21 | 20,96 | -288.682 | 136.667.165 |
| 2021-05-12 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -411 | 6.534.153 | -0,01 | 22,46 | -9.231 | 146.757.076 |
| 2021-05-12 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -16.722 | 6.534.564 | -0,26 | 21,78 | -364.205 | 142.322.804 |
| 2021-05-06 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -59 | 6.551.286 | 0,00 | 23,09 | -1.362 | 151.269.194 |
| 2021-05-06 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.113 | 6.551.345 | -0,15 | 22,52 | -227.745 | 147.536.289 |
| 2021-05-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -12.899.925 | 0 | -100,00 | ||||
| 2021-05-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -38.817.998 | 0 | -100,00 | ||||
| 2021-05-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
P - Purchase | 245.000 | 6.672.183 | 3,81 | 16,00 | 3.920.000 | 106.754.928 | |
| 2021-05-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
C - Conversion | 1.488.033 | 6.427.183 | 30,13 | ||||
| 2021-05-06 |
|
4 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
C - Conversion | 4.477.742 | 4.939.150 | 970,45 | ||||
| 2021-05-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.500 | 6.561.458 | -0,05 | 23,33 | -81.655 | 153.078.815 |
| 2021-05-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -26.230 | 6.564.958 | -0,40 | 23,03 | -604.077 | 151.190.983 |
| 2021-05-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -4.401 | 6.591.188 | -0,07 | 23,45 | -103.203 | 154.563.359 |
| 2021-05-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -26.365 | 6.595.589 | -0,40 | 23,03 | -607.186 | 151.896.415 |
| 2021-05-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -268.023 | 6.621.954 | -3,89 | 22,35 | -5.990.314 | 148.000.672 |
| 2021-04-29 | 3 | HOWL |
Werewolf Therapeutics, Inc.
Common Stock |
461.408 | ||||||||
| 2021-04-29 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -21.781 | 6.889.977 | -0,32 | 22,54 | -490.944 | 155.300.082 |
| 2021-04-29 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -45.511 | 6.911.758 | -0,65 | 22,02 | -1.002.152 | 152.196.911 |
| 2021-04-29 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -36.803 | 6.957.269 | -0,53 | 22,01 | -810.034 | 153.129.491 |
| 2021-04-29 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -14.219 | 6.994.072 | -0,20 | 21,64 | -307.699 | 151.351.718 |
| 2021-04-29 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -8.328 | 7.008.291 | -0,12 | 21,26 | -177.053 | 148.996.267 |
| 2021-04-29 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.501 | 7.016.619 | -0,05 | 20,99 | -73.486 | 147.278.833 |
| 2021-04-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -555 | 7.020.120 | -0,01 | 19,48 | -10.811 | 136.751.938 |
| 2021-04-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -8.417 | 7.020.675 | -0,12 | 18,94 | -159.418 | 132.971.584 |
| 2021-04-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -834 | 7.029.092 | -0,01 | 19,09 | -15.921 | 134.185.366 |
| 2021-04-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -21.415 | 7.029.926 | -0,30 | 18,70 | -400.460 | 131.459.616 |
| 2021-04-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -100 | 7.051.341 | 0,00 | 20,08 | -2.008 | 141.590.927 |
| 2021-04-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -9.956 | 7.051.441 | -0,14 | 19,29 | -192.051 | 136.022.297 |
| 2021-04-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -300 | 7.061.397 | 0,00 | 20,56 | -6.168 | 145.182.322 |
| 2021-04-20 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -5.547 | 7.061.697 | -0,08 | 19,82 | -109.942 | 139.962.835 |
| 2021-04-15 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -8.696 | 7.067.244 | -0,12 | 20,49 | -178.181 | 144.807.830 |
| 2021-04-15 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -12.806 | 7.075.940 | -0,18 | 20,83 | -266.749 | 147.391.830 |
| 2021-04-15 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.000 | 7.088.746 | -0,01 | 20,06 | -20.060 | 142.200.245 |
| 2021-04-15 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -2.362 | 7.089.746 | -0,03 | 20,08 | -47.429 | 142.362.100 |
| 2021-04-15 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -13.692 | 7.092.108 | -0,19 | 19,35 | -264.940 | 137.232.290 |
| 2021-04-13 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -400 | 7.105.800 | -0,01 | 22,68 | -9.072 | 161.159.544 |
| 2021-04-13 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.700 | 7.106.200 | -0,09 | 21,52 | -144.184 | 152.925.424 |
| 2021-04-13 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -13.528 | 7.112.900 | -0,19 | 20,72 | -280.300 | 147.379.288 |
| 2021-04-13 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.300 | 7.126.428 | -0,14 | 23,67 | -243.801 | 168.682.551 |
| 2021-04-13 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -200 | 6.004.368 | 0,00 | 29,99 | -5.998 | 180.070.996 |
| 2021-04-09 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -414 | 6.004.568 | -0,01 | 31,01 | -12.838 | 186.201.654 |
| 2021-04-09 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -31.890 | 6.004.982 | -0,53 | 30,51 | -972.964 | 183.212.001 |
| 2021-04-09 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
J - Other | -15.670 | 6.036.872 | -0,26 | ||||
| 2021-04-09 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.300 | 6.052.542 | -0,02 | 33,84 | -43.992 | 204.818.021 |
| 2021-04-09 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.083 | 6.053.842 | -0,05 | 32,84 | -101.246 | 198.808.171 |
| 2021-04-09 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
S - Sale | X | -5.295 | 6.056.925 | -0,09 | 32,07 | -169.811 | 194.245.585 |
| 2021-03-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 24.271 | 4.672.838 | 0,52 | ||||
| 2021-03-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | -695.000 | 4.697.109 | -12,89 | 28,18 | -19.585.100 | 132.364.532 | |
| 2021-02-12 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -183.051 | 3.238.306 | -5,35 | 20,00 | -3.661.020 | 64.766.120 |
| 2021-02-09 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -9.400 | 3.421.357 | -0,27 | 20,25 | -190.350 | 69.282.479 |
| 2021-02-09 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -72.128 | 3.430.757 | -2,06 | 20,04 | -1.445.445 | 68.752.370 |
| 2021-02-09 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.172 | 3.502.885 | -0,29 | 20,01 | -203.542 | 70.092.729 |
| 2021-02-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -29.730 | 3.513.057 | -0,84 | 20,37 | -605.600 | 71.560.971 |
| 2021-02-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -41.922 | 3.542.787 | -1,17 | 20,21 | -847.244 | 71.599.725 |
| 2021-02-04 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -48.421 | 3.584.709 | -1,33 | 20,13 | -974.715 | 72.160.192 |
| 2021-01-27 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -706.825 | 3.633.130 | -16,29 | 20,00 | -14.136.500 | 72.662.600 |
| 2021-01-27 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.363 | 4.339.955 | -0,03 | 21,08 | -28.732 | 91.486.251 |
| 2021-01-27 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -13.006 | 4.341.318 | -0,30 | 21,23 | -276.117 | 92.166.181 |
| 2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -24.695 | 4.354.324 | -0,56 | 21,72 | -536.375 | 94.575.917 |
| 2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -200 | 4.379.019 | 0,00 | 23,77 | -4.754 | 104.089.282 |
| 2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -4.887 | 4.379.219 | -0,11 | 22,61 | -110.495 | 99.014.142 |
| 2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -20.979 | 4.384.106 | -0,48 | 22,11 | -463.846 | 96.932.584 |
| 2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
J - Other | X | -101.646 | 4.405.085 | -2,26 | |||
| 2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -2.000 | 4.506.731 | -0,04 | 24,71 | -49.420 | 111.361.323 |
| 2021-01-22 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | X | -15.694 | 4.508.731 | -0,35 | 23,95 | -375.871 | 107.984.107 |
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -649.030 | 0 | -100,00 | ||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -2.276.692 | 0 | -100,00 | ||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3.551.640 | 0 | -100,00 | ||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series Seed Convertible Preferred Stock |
C - Conversion | -1.136.525 | 0 | -100,00 | ||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Common Stock |
P - Purchase | 300.000 | 7.913.887 | 3,94 | 21,00 | 6.300.000 | 166.191.627 | |
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Common Stock |
C - Conversion | 649.030 | 7.613.887 | 9,32 | ||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Common Stock |
C - Conversion | 2.276.692 | 6.964.857 | 48,56 | ||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Common Stock |
C - Conversion | 3.551.640 | 4.688.165 | 312,50 | ||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Common Stock |
C - Conversion | 1.136.525 | 1.136.525 | |||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Stock Option (Right to Buy) |
J - Other | 88.824 | 88.824 | |||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Stock Option (Right to Buy) |
J - Other | 262.114 | 262.114 | |||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series C Convertible Preferred Stock |
J - Other | 649.030 | 649.030 | |||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series B Convertible Preferred Stock |
J - Other | 2.276.692 | 2.276.692 | |||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series A Convertible Preferred Stock |
J - Other | 3.551.640 | 3.551.640 | |||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Series Seed Convertible Preferred Stock |
J - Other | 1.136.525 | 1.136.525 | |||||
| 2021-01-14 |
|
4 | CGEM |
Cullinan Management, Inc.
Common Stock |
J - Other | 281.268 | 281.268 | |||||
| 2021-01-07 | 3 | CGEM |
Cullinan Management, Inc.
Common Stock |
281.268 | ||||||||
| 2020-10-21 |
|
4/A | ITOS |
iTeos Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 16.608 | 0 | -100,00 | ||||
| 2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series B Preferred Stock |
C - Conversion | 700.453 | 0 | -100,00 | ||||
| 2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series B Preferred Stock |
C - Conversion | 775.975 | 0 | -100,00 | ||||
| 2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series A-1 Preferred Stock |
C - Conversion | 1.525.348 | 0 | -100,00 | ||||
| 2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Series A-1 Preferred Stock |
C - Conversion | 1.783.879 | 0 | -100,00 | ||||
| 2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 151.224 | 2.377.025 | 6,79 | 15,00 | 2.268.360 | 35.655.375 | |
| 2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
P - Purchase | 173.776 | 2.849.453 | 6,49 | 15,00 | 2.606.640 | 42.741.795 | |
| 2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 700.453 | 2.225.801 | 45,92 | ||||
| 2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 775.975 | 2.675.677 | 40,85 | ||||
| 2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 1.525.348 | 1.525.348 | |||||
| 2020-10-08 |
|
4 | ONCR |
Oncorus, Inc.
Common Stock |
C - Conversion | 1.783.879 | 1.899.702 | 1.540,18 | ||||
| 2020-10-01 | 3 | ONCR |
Oncorus, Inc.
Common Stock |
115.823 | ||||||||
| 2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -26.176 | 0 | -100,00 | ||||
| 2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -70.492 | 0 | -100,00 | ||||
| 2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1.326.313 | 0 | -100,00 | ||||
| 2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -275.932 | 0 | -100,00 | ||||
| 2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -743.076 | 0 | -100,00 | ||||
| 2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -13.980.992 | 0 | -100,00 | ||||
| 2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Common Stock |
C - Conversion | 91.081 | 91.081 | |||||
| 2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Common Stock |
C - Conversion | 245.279 | 245.279 | |||||
| 2020-09-23 |
|
4 | DYN |
Dyne Therapeutics, Inc.
Common Stock |
C - Conversion | 4.614.943 | 4.614.943 | |||||
| 2020-08-05 |
|
4 | ALVR |
Allovir, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -20.000.000 | 0 | -100,00 | ||||
| 2020-08-05 |
|
4 | ALVR |
Allovir, Inc.
Common Stock |
C - Conversion | 13.420.970 | 13.420.970 | |||||
| 2020-07-31 |
|
4 | ALVR |
Allovir, Inc.
Stock Option (Right to Buy) |
A - Award | 22.500 | 22.500 | |||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2.600.628 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -29.440 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -79.281 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -1.491.666 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -81.295 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -157.529 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2.361.805 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -4.211.330 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -47.674 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -128.384 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -2.415.530 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -131.645 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -255.094 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -3.824.591 | 0 | -100,00 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 160.000 | 2.355.557 | 7,29 | 19,00 | 3.040.000 | 44.755.583 | |
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 1.121 | 25.974 | 4,51 | 19,00 | 21.299 | 493.506 | |
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 3.020 | 69.951 | 4,51 | 19,00 | 57.380 | 1.329.069 | |
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 56.814 | 1.316.139 | 4,51 | 19,00 | 1.079.466 | 25.006.641 | |
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 3.096 | 71.727 | 4,51 | 19,00 | 58.824 | 1.362.813 | |
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 5.994 | 138.985 | 4,51 | 19,00 | 113.886 | 2.640.715 | |
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
P - Purchase | 89.955 | 2.083.887 | 4,51 | 19,00 | 1.709.145 | 39.593.853 | |
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 797.983 | 2.195.557 | 57,10 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 9.033 | 24.853 | 57,10 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 24.326 | 66.931 | 57,10 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 457.706 | 1.259.325 | 57,10 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 24.944 | 68.381 | 57,43 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 48.336 | 132.991 | 57,10 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 724.702 | 1.993.932 | 57,10 | ||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 1.397.574 | 1.397.574 | |||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 15.820 | 15.820 | |||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 42.605 | 42.605 | |||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 801.619 | 801.619 | |||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 43.687 | 43.687 | |||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 84.655 | 84.655 | |||||
| 2020-07-30 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Common Stock |
C - Conversion | 1.269.230 | 1.269.230 | |||||
| 2020-07-29 | 3 | ALVR |
Allovir, Inc.
Common Stock |
60.394 | ||||||||
| 2020-07-29 | 3 | ALVR |
Allovir, Inc.
Common Stock |
60.394 | ||||||||
| 2020-07-29 | 3 | ALVR |
Allovir, Inc.
Common Stock |
60.394 | ||||||||
| 2020-07-24 |
|
4 | ITOS |
iTeos Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 16.608 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -1.288.948 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class A Preferred Shares |
C - Conversion | -3.603.161 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
P - Purchase | 500.000 | 5.392.109 | 10,22 | 20,00 | 10.000.000 | 107.842.180 | |
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 1.288.948 | 4.892.109 | 35,77 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 3.603.161 | 3.603.161 | |||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series B Preferred Stock |
C - Conversion | -1.750.000 | 0 | -100,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series B Preferred Stock |
C - Conversion | -217.500 | 0 | -100,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series B Preferred Stock |
C - Conversion | -1.586.623 | 0 | -100,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series B Preferred Stock |
C - Conversion | -105.825 | 0 | -100,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series B Preferred Stock |
C - Conversion | -32.500 | 0 | -100,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series B Preferred Stock |
C - Conversion | -57.552 | 0 | -100,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series A Preferred Stock |
C - Conversion | -15.000.000 | 0 | -100,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series A Preferred Stock |
C - Conversion | -2.174.998 | 0 | -100,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series A Preferred Stock |
C - Conversion | -13.599.621 | 0 | -100,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series A Preferred Stock |
C - Conversion | -907.073 | 0 | -100,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series A Preferred Stock |
C - Conversion | -325.002 | 0 | -100,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Series A Preferred Stock |
C - Conversion | -493.306 | 0 | -100,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
P - Purchase | 1.373.333 | 1.569.235 | 701,03 | 15,00 | 20.599.995 | 23.538.525 | |
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 282.540 | 2.704.315 | 11,67 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 35.115 | 386.270 | 10,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 256.163 | 2.451.844 | 11,67 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 17.085 | 163.532 | 11,67 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 5.247 | 57.716 | 10,00 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 9.291 | 88.935 | 11,67 | ||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 2.421.775 | 2.421.775 | |||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 351.155 | 351.155 | |||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 2.195.681 | 2.195.681 | |||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 146.447 | 146.447 | |||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 52.469 | 52.469 | |||||
| 2019-02-21 |
|
4 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
C - Conversion | 79.644 | 79.644 | |||||
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy) |
X - Other | -101.675 | 0 | -100,00 | ||||
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy) |
X - Other | -152.514 | 0 | -100,00 | ||||
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy) |
X - Other | -50.837 | 0 | -100,00 | ||||
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy) |
X - Other | -171.579 | 0 | -100,00 | ||||
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy) |
X - Other | -57.192 | 0 | -100,00 | ||||
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy) |
X - Other | -25.418 | 0 | -100,00 | ||||
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -835.705 | 0 | -100,00 | ||||
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -3.157.506 | 0 | -100,00 | ||||
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3.050.329 | 0 | -100,00 | ||||
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
P - Purchase | 500.000 | 8.422.847 | 6,31 | 14,00 | 7.000.000 | 117.919.858 | |
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
S - Sale | -1.971 | 7.922.847 | -0,02 | 14,00 | -27.594 | 110.919.858 | |
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
X - Other | 559.215 | 7.924.818 | 7,59 | 0,05 | 27.513 | 389.901 | |
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
C - Conversion | 835.705 | 7.365.603 | 12,80 | ||||
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
C - Conversion | 3.157.506 | 6.529.898 | 93,63 | ||||
| 2019-02-14 |
|
4 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
C - Conversion | 3.050.329 | 3.372.392 | 947,12 | ||||
| 2019-02-13 | 3 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
391.804 | ||||||||
| 2019-02-13 | 3 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
391.804 | ||||||||
| 2019-02-13 | 3 | TCRR |
TCR2 THERAPEUTICS INC.
Common Stock |
391.804 | ||||||||
| 2019-02-07 | 3 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
644.126 | ||||||||
| 2019-02-07 | 3 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
644.126 | ||||||||
| 2019-02-07 | 3 | HARP |
Harpoon Therapeutics, Inc.
Common Stock |
644.126 | ||||||||
| 2017-10-11 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A-1 Junior Preferred Stock |
C - Conversion | -15.887.703 | 0 | -100,00 | ||||
| 2017-10-11 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A Preferred Stock |
C - Conversion | -7.651.831 | 0 | -100,00 | ||||
| 2017-10-11 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 100.000 | 2.696.392 | 3,85 | 17,00 | 1.700.000 | 45.838.664 | |
| 2017-10-11 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 2.567.014 | 2.596.392 | 8.737,88 | ||||
| 2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
| 2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
| 2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
| 2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
| 2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
| 2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
| 2017-10-04 | 3 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
58.756 | ||||||||
| 2017-02-22 |
|
4 | RDUS |
Radius Health, Inc.
Stock Option (Right to Buy) |
A - Award | 27.500 | 27.500 | |||||
| 2016-09-29 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
J - Other | -1.943.751 | 3.887.502 | -33,33 | ||||
| 2016-06-13 |
|
4 | CHMA |
CHIASMA, INC
Stock Option (Right to Buy) |
A - Award | 10.000 | 10.000 | |||||
| 2016-06-02 |
|
4 | RDUS |
Radius Health, Inc.
Stock Option (Right to Buy) |
A - Award | 27.500 | 27.500 | |||||
| 2016-03-09 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -312.085 | 0 | -100,00 | ||||
| 2016-03-09 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -718.396 | 0 | -100,00 | ||||
| 2016-03-09 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock |
C - Conversion | -1.138.210 | 0 | -100,00 | ||||
| 2016-03-09 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 312.085 | 2.168.691 | 16,81 | ||||
| 2016-03-09 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 718.396 | 1.856.606 | 63,12 | ||||
| 2016-03-09 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 1.138.210 | 1.138.210 | |||||
| 2016-02-12 |
|
4 | RDUS |
Radius Health, Inc.
Stock Option (Right to Buy) |
A - Award | 27.500 | 27.500 | |||||
| 2015-10-20 |
|
4 | CERC |
Cerecor Inc.
Series B Convertible Preferred Stock |
C - Conversion | -16.672.224 | 0 | -100,00 | ||||
| 2015-10-20 |
|
4 | CERC |
Cerecor Inc.
Common Stock |
C - Conversion | 595.436 | 595.436 | |||||
| 2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Series E Preferred Stock |
C - Conversion | -13.000.000 | 0 | -100,00 | ||||
| 2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Series D' Preferred Stock |
C - Conversion | -16.066.669 | 0 | -100,00 | ||||
| 2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Series C' Preferred Stock |
C - Conversion | -22.721.988 | 0 | -100,00 | ||||
| 2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Series B-1' Preferred Stock |
C - Conversion | -95.225 | 0 | -100,00 | ||||
| 2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Common Stock |
C - Conversion | 1.423.566 | 5.681.544 | 33,43 | ||||
| 2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Common Stock |
C - Conversion | 1.759.381 | 4.257.978 | 70,41 | ||||
| 2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Common Stock |
C - Conversion | 2.488.171 | 2.498.597 | 23.865,06 | ||||
| 2015-07-21 |
|
4 | CHMA |
CHIASMA, INC
Common Stock |
C - Conversion | 10.426 | 10.426 | |||||
| 2015-05-26 |
|
4 | RDUS |
Radius Health, Inc.
Stock Option (Right to Buy) |
A - Award | 15.000 | 15.000 | |||||
| 2014-12-19 |
|
4 | RDUS |
Radius Health, Inc.
Stock Option (Right to Buy) |
A - Award | 30.000 | 30.000 | |||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -184.242 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -114.537 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -71.638 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -859 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -3.511 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -4.346 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.468 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -1.340 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -5.477 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -6.779 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -2.291 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -3.752 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -15.327 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -18.975 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -6.414 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -44.395 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -181.364 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -224.528 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -75.899 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -2.985 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -12.194 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -15.096 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -5.103 | 0 | -100,00 | ||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 2.141.547 | 2.141.547 | |||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 59.445 | 59.445 | |||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 92.734 | 92.734 | |||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 259.567 | 259.567 | |||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 3.071.454 | 3.071.454 | |||||
| 2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 206.506 | 206.506 | |||||
| 2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Warrant to Purchase Common Stock (Right to Buy) |
C - Conversion | 37.369 | 37.369 | |||||
| 2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Warrant to Purchase Series D Preferred Stock (Right to Buy) |
C - Conversion | -1.516.122 | 0 | -100,00 | ||||
| 2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -10.266.940 | 0 | -100,00 | ||||
| 2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -15.400.411 | 0 | -100,00 | ||||
| 2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -2.947.605 | 0 | -100,00 | ||||
| 2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -6.000.000 | 0 | -100,00 | ||||
| 2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -20.757.635 | 0 | -100,00 | ||||
| 2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 253.066 | 1.776.692 | 16,61 | ||||
| 2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 379.599 | 1.523.626 | 33,18 | ||||
| 2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 114.942 | 1.144.027 | 11,17 | ||||
| 2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 230.756 | 1.029.085 | 28,90 | ||||
| 2014-04-23 |
|
4 | TRIV |
TriVascular Technologies, Inc.
Common Stock |
C - Conversion | 798.329 | 798.329 | |||||
| 2014-03-12 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -600.000 | 2.751.048 | -17,90 | 20,02 | -12.012.000 | 55.075.981 | |
| 2014-03-11 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -26.713 | 0 | -100,00 | 20,16 | -538.534 | ||
| 2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | 37.117 | 37.117 | |||||
| 2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | 12.247 | 12.393 | 8.388,36 | ||||
| 2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | 15.310 | 17.937 | 582,79 | ||||
| 2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | 20.876 | 22.767 | 1.103,97 | ||||
| 2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | 20.876 | 22.767 | 1.103,97 | ||||
| 2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | 20.876 | 38.386 | 119,22 | ||||
| 2014-03-05 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
J - Other | -1.000.000 | 3.351.048 | -22,98 | ||||
| 2014-02-11 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
S - Sale | -466.666 | 2.413.819 | -16,20 | 29,25 | -13.649.980 | 70.604.206 | |
| 2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Warrant to Purchase Common Stock (Right to Buy) |
C - Conversion | 32.220 | 32.220 | |||||
| 2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Warrant to Purchase Series B Preferred Stock (Right to Buy) |
C - Conversion | -265.837 | 0 | -100,00 | ||||
| 2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Series B Convertible Preferred Stock |
C - Conversion | -8.333.334 | 0 | -100,00 | ||||
| 2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Common Stock |
P - Purchase | 165.265 | 1.192.080 | 16,09 | 11,00 | 1.817.915 | 13.112.880 | |
| 2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Common Stock |
J - Other | 16.716 | 1.026.815 | 1,65 | 11,00 | 183.876 | 11.294.965 | |
| 2013-08-01 |
|
4 | CNAT |
Conatus Pharmaceuticals Inc
Common Stock |
C - Conversion | 1.010.099 | 1.010.099 | |||||
| 2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Series C Preferred Stock |
C - Conversion | -375.000 | 0 | -100,00 | ||||
| 2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Series B Preferred Stock |
C - Conversion | -1.333.333 | 0 | -100,00 | ||||
| 2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Series A Preferred Stock |
C - Conversion | -4.000.000 | 0 | -100,00 | ||||
| 2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
P - Purchase | 500.000 | 4.351.050 | 12,98 | 6,00 | 3.000.000 | 26.106.300 | |
| 2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
C - Conversion | 225.631 | 3.851.050 | 6,22 | ||||
| 2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
C - Conversion | 802.246 | 3.625.419 | 28,42 | ||||
| 2013-07-02 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
C - Conversion | 2.406.739 | 2.823.173 | 577,94 | ||||
| 2013-06-26 | 3 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
180.505 | ||||||||
| 2013-06-06 |
|
4 | EPZM |
Epizyme, Inc.
Series B Preferred Stock |
C - Conversion | -1.176.472 | 0 | -100,00 | ||||
| 2013-06-06 |
|
4 | EPZM |
Epizyme, Inc.
Series A Preferred Stock |
C - Conversion | -6.930.000 | 0 | -100,00 | ||||
| 2013-06-06 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
C - Conversion | 392.156 | 2.880.485 | 15,76 | ||||
| 2013-06-06 |
|
4 | EPZM |
Epizyme, Inc.
Common Stock |
C - Conversion | 2.309.998 | 2.488.329 | 1.295,34 | ||||
| 2013-05-30 | 3 | EPZM |
Epizyme, Inc.
Common Stock |
178.331 | ||||||||
| 2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Common Stock Warrant |
A - Award | 179.095 | 179.095 | |||||
| 2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Series B Convertible Preferred Stock |
A - Award | 71.638 | 71.638 | 61,42 | 4.400.006 | 4.400.006 | ||
| 2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Common Stock Warrant |
A - Award | 3.670 | 3.670 | |||||
| 2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Series B Convertible Preferred Stock |
A - Award | 1.468 | 1.468 | 61,42 | 90.165 | 90.165 | ||
| 2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Common Stock Warrant |
A - Award | 5.728 | 5.728 | |||||
| 2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Series B Convertible Preferred Stock |
A - Award | 2.291 | 2.291 | 61,42 | 140.713 | 140.713 | ||
| 2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Common Stock Warrant |
A - Award | 16.035 | 16.035 | |||||
| 2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Series B Convertible Preferred Stock |
A - Award | 6.414 | 6.414 | 61,42 | 393.948 | 393.948 | ||
| 2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Common Stock Warrant |
A - Award | 189.748 | 189.748 | |||||
| 2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Series B Convertible Preferred Stock |
A - Award | 75.899 | 75.899 | 61,42 | 4.661.717 | 4.661.717 | ||
| 2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Common Stock Warrant |
A - Award | 12.758 | 12.758 | |||||
| 2013-04-25 |
|
4 | NONE |
Radius Health, Inc.
Series B Convertible Preferred Stock |
A - Award | 5.103 | 5.103 | 61,42 | 313.426 | 313.426 | ||
| 2013-03-13 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -500.000 | 2.790.479 | -15,20 | 27,86 | -13.930.000 | 77.742.745 | |
| 2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Series D Preferred Stock |
C - Conversion | -275.539 | 0 | -100,00 | ||||
| 2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -337.622 | 0 | -100,00 | ||||
| 2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Series B-2 Preferred Stock |
C - Conversion | -1.949.879 | 0 | -100,00 | ||||
| 2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 313.527 | 2.632.928 | 13,52 | ||||
| 2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 369.522 | 2.319.401 | 18,95 | ||||
| 2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 1.949.879 | 1.949.879 | |||||
| 2012-07-10 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -1.624.574 | 1.275.886 | -56,01 | 0,31 | -498.744 | 391.697 | |
| 2012-07-10 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -671.217 | 2.900.460 | -18,79 | 0,29 | -195.324 | 844.034 | |
| 2012-07-05 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -98.210 | 3.571.677 | -2,68 | 0,29 | -28.481 | 1.035.786 | |
| 2012-07-05 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -80.348 | 3.669.887 | -2,14 | 0,29 | -23.301 | 1.064.267 | |
| 2012-07-02 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -19.500 | 3.750.235 | -0,52 | 0,29 | -5.655 | 1.087.568 | |
| 2012-06-21 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -12.000 | 3.759.735 | -0,32 | 0,29 | -3.480 | 1.090.323 | |
| 2012-06-19 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -1.450 | 3.781.735 | -0,04 | 0,29 | -420 | 1.096.703 | |
| 2012-06-07 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -8.400 | 3.783.185 | -0,22 | 0,29 | -2.436 | 1.097.124 | |
| 2012-06-07 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -29.555 | 3.791.585 | -0,77 | 0,29 | -8.571 | 1.099.560 | |
| 2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -29.850 | 3.821.140 | -0,78 | 0,30 | -8.955 | 1.146.342 | |
| 2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -51.007 | 3.850.990 | -1,31 | 0,30 | -15.302 | 1.155.297 | |
| 2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -15.300 | 3.901.997 | -0,39 | 0,30 | -4.622 | 1.178.793 | |
| 2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -293.015 | 3.917.297 | -6,96 | 0,30 | -87.904 | 1.175.189 | |
| 2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -135.250 | 4.210.312 | -3,11 | 0,30 | -40.629 | 1.264.778 | |
| 2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -287.000 | 4.345.562 | -6,20 | 0,30 | -86.990 | 1.317.140 | |
| 2012-03-08 |
|
4 | VSTM |
Verastem, Inc.
Stock Option (Right to Buy) |
A - Award | 12.500 | 12.500 | |||||
| 2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Series C Preferred Stock |
C - Conversion | -266.666 | 0 | -100,00 | ||||
| 2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Series B Preferred Stock |
C - Conversion | -2.500.000 | 0 | -100,00 | ||||
| 2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Series A Preferred Stock |
C - Conversion | -4.000.000 | 0 | -100,00 | ||||
| 2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Common Stock |
P - Purchase | 3.740 | 3.740 | 10,00 | 37.400 | 37.400 | ||
| 2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Common Stock |
P - Purchase | 96.260 | 2.029.593 | 4,98 | 10,00 | 962.600 | 20.295.930 | |
| 2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Common Stock |
C - Conversion | 76.190 | 1.933.333 | 4,10 | ||||
| 2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Common Stock |
C - Conversion | 714.286 | 1.857.143 | 62,50 | ||||
| 2012-02-03 |
|
4 | VSTM |
Verastem, Inc.
Common Stock |
C - Conversion | 1.142.857 | 1.142.857 |
